Evidence map›Paper›PMID 25060055›Full record

ArticleJournal of the American Society of Nephrology : JASN2015

The biomarker niche for fibroblast growth factor 23 testing in CKD.

Myles Wolf

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. FGF23BMC biotechnology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Myles WolfDivision of Nephrology and Hypertension, Department of Medicine, Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois myles.wolf@northwestern.edu.

Funding

FGF23 and Cardiovascular Disease in CKDR01DK081374 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2008 to 2016
$4.2M
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney DiseaseR01DK076116 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2007 to 2016
$2.9M
FGF-23 and clinical outcomes in ADPKD patientsR01DK094796 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CHONCHOL, MICHEL BENJAMIN, GITOMER, BERENICE YOLANDE · 2012 to 2016
$2.3M
Pilot Studies Targeting Mineral Metabolism in CKDU01DK099930 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ISAKOVA, TAMARA · 2013 to 2018
$1.8M
Mentored Patient Oriented Research in Mineral MetabolismK24DK093723 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2012 to 2016
$803k
NIDDK NIH HHS K24 DK093723NIDDK NIH HHS K24-DK093723NIDDK NIH HHS R01 DK076116NIDDK NIH HHS R01-DK076116NIDDK NIH HHS R01 DK081374NIDDK NIH HHS R01-DK081374NIDDK NIH HHS R01 DK094796NIDDK NIH HHS R01-DK094796NIDDK NIH HHS U01 DK099930NIDDK NIH HHS U01-DK099930
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression RegulationFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansKidney DiseasesMaleFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsCKDESRDFGF-23

Identifiers

PMID25060055
PMCPMC4279750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.